A Double-blind, Parallel Group, Placebo-Controlled Outpatient Trial of PD 00200390 in Adults With Nonrestorative Sleep
PD 0200390 Dose-Ranging Trial: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Outpatient Trial of PD 0200390 in Adults With Nonrestorative Sleep
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
British Columbia
-
Kelowna, British Columbia, Canada, V1Y 3G8
- Pfizer Investigational Site
-
Kelowna, British Columbia, Canada, V1Y 4R9
- Pfizer Investigational Site
-
-
Ontario
-
Etobicoke, Ontario, Canada, M9W 6V1
- Pfizer Investigational Site
-
Kitchener, Ontario, Canada, N2G 1G1
- Pfizer Investigational Site
-
Parry Sound, Ontario, Canada, P2A 3A4
- Pfizer Investigational Site
-
Toronto, Ontario, Canada, M6J 3S3
- Pfizer Investigational Site
-
Toronto, Ontario, Canada, M4P 1P2
- Pfizer Investigational Site
-
-
-
-
Arizona
-
Glendale, Arizona, United States, 85306
- Pfizer Investigational Site
-
Phoenix, Arizona, United States, 85306
- Pfizer Investigational Site
-
Tucson, Arizona, United States, 85712
- Pfizer Investigational Site
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Pfizer Investigational Site
-
-
California
-
Los Angeles, California, United States, 90048
- Pfizer Investigational Site
-
Pasadena, California, United States, 91106
- Pfizer Investigational Site
-
San Diego, California, United States, 92103
- Pfizer Investigational Site
-
San Francisco, California, United States, 94105
- Pfizer Investigational Site
-
Tustin, California, United States, 92780
- Pfizer Investigational Site
-
-
Colorado
-
Wheat Ridge, Colorado, United States, 80033
- Pfizer Investigational Site
-
-
Connecticut
-
North Haven, Connecticut, United States, 06473
- Pfizer Investigational Site
-
Wallingford, Connecticut, United States, 06492
- Pfizer Investigational Site
-
-
Florida
-
DeLand, Florida, United States, 32720
- Pfizer Investigational Site
-
Miami, Florida, United States, 33143
- Pfizer Investigational Site
-
Naples, Florida, United States, 34110
- Pfizer Investigational Site
-
Orange City, Florida, United States, 32763
- Pfizer Investigational Site
-
Orlando, Florida, United States, 32806
- Pfizer Investigational Site
-
Pembroke Pines, Florida, United States, 33026
- Pfizer Investigational Site
-
South Miami, Florida, United States, 33143
- Pfizer Investigational Site
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Pfizer Investigational Site
-
Atlanta, Georgia, United States, 30328
- Pfizer Investigational Site
-
Gainesville, Georgia, United States, 30501
- Pfizer Investigational Site
-
-
Illinois
-
Chicago, Illinois, United States, 60634
- Pfizer Investigational Site
-
-
Indiana
-
Indianapolis, Indiana, United States, 46260
- Pfizer Investigational Site
-
-
Kansas
-
Overland Park, Kansas, United States, 66212
- Pfizer Investigational Site
-
-
Kentucky
-
Crestview Hills, Kentucky, United States, 41017
- Pfizer Investigational Site
-
Lexington, Kentucky, United States, 40504
- Pfizer Investigational Site
-
Lexington, Kentucky, United States, 40513
- Pfizer Investigational Site
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70809
- Pfizer Investigational Site
-
-
Maryland
-
Chevy Chase, Maryland, United States, 20815
- Pfizer Investigational Site
-
-
Massachusetts
-
Brighton, Massachusetts, United States, 02135
- Pfizer Investigational Site
-
N. Dartmouth, Massachusetts, United States, 02747
- Pfizer Investigational Site
-
-
Missouri
-
Chesterfield, Missouri, United States, 63017
- Pfizer Investigational Site
-
St. Louis, Missouri, United States, 63108
- Pfizer Investigational Site
-
-
Nevada
-
Las Vegas, Nevada, United States, 89146
- Pfizer Investigational Site
-
Las Vegas, Nevada, United States, 89104
- Pfizer Investigational Site
-
-
New York
-
West Seneca, New York, United States, 14224
- Pfizer Investigational Site
-
-
North Carolina
-
Cary, North Carolina, United States, 27511
- Pfizer Investigational Site
-
Raleigh, North Carolina, United States, 27612
- Pfizer Investigational Site
-
Raleigh, North Carolina, United States, 27607-6520
- Pfizer Investigational Site
-
Salisbury, North Carolina, United States, 28144
- Pfizer Investigational Site
-
Winston Salem, North Carolina, United States, 27103
- Pfizer Investigational Site
-
Winston-Salem, North Carolina, United States, 27103
- Pfizer Investigational Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45227
- Pfizer Investigational Site
-
-
Oklahoma
-
Oklahoma, Oklahoma, United States, 73112
- Pfizer Investigational Site
-
-
Pennsylvania
-
Clarks Summit, Pennsylvania, United States, 18411
- Pfizer Investigational Site
-
Uniontown, Pennsylvania, United States, 15401
- Pfizer Investigational Site
-
-
Rhode Island
-
Warwick, Rhode Island, United States, 02886
- Pfizer Investigational Site
-
West Warwick, Rhode Island, United States, 02893
- Pfizer Investigational Site
-
-
South Carolina
-
Columbia, South Carolina, United States, 29201
- Pfizer Investigational Site
-
-
Texas
-
Austin, Texas, United States, 78756
- Pfizer Investigational Site
-
Dallas, Texas, United States, 75230
- Pfizer Investigational Site
-
Irving, Texas, United States, 75039
- Pfizer Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Awake unrestored or unrefreshed, associated with significant distress or impairment in social, occupational, or other important areas of functioning during the daytime, for at least 3 nights for the past 3 months prior to screening
- Self-report wake after sleep onset <45 mins for past 3 mos; self-report latency to sleep onset <20 mins for past 3 mos
- PSG (Polysomnography) sleep criteria of wake after sleep onset < 45 mins; Latency to persistent sleep <20 mins.
Exclusion Criteria:
- MAP (Multivariable Apnea Risk index) index > or = 0.5 at screening
- BMI = or > 32 kg/m2
- History or presence of breathing related disorders
- PSG findings consistent with and periodic limb movement disorder, narcolepsy or other dyssomnia or parasomnia including apnea-hypopnea index > 10/hr; or period limb movement with arousal index > 10/hr.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
oral placebo daily dose, 3 capsules per dose during a six week treatment period.
|
|
Experimental: 50 mg
|
oral 15 mg daily dose, 3 capsules per dose during a six week treatment period.
oral 25 mg daily dose, 3 capsules per dose during a six week treatment period.
oral 35 mg daily dose, 3 capsules per dose during a six week treatment period.
oral 5 mg daily dose, 3 capsules per dose during a six week treatment period.
oral 50 mg daily dose, 3 capsules per dose during a six week treatment period.
|
|
Experimental: 15 mg
|
oral 15 mg daily dose, 3 capsules per dose during a six week treatment period.
oral 25 mg daily dose, 3 capsules per dose during a six week treatment period.
oral 35 mg daily dose, 3 capsules per dose during a six week treatment period.
oral 5 mg daily dose, 3 capsules per dose during a six week treatment period.
oral 50 mg daily dose, 3 capsules per dose during a six week treatment period.
|
|
Experimental: 25 mg
|
oral 15 mg daily dose, 3 capsules per dose during a six week treatment period.
oral 25 mg daily dose, 3 capsules per dose during a six week treatment period.
oral 35 mg daily dose, 3 capsules per dose during a six week treatment period.
oral 5 mg daily dose, 3 capsules per dose during a six week treatment period.
oral 50 mg daily dose, 3 capsules per dose during a six week treatment period.
|
|
Experimental: 35 mg
|
oral 15 mg daily dose, 3 capsules per dose during a six week treatment period.
oral 25 mg daily dose, 3 capsules per dose during a six week treatment period.
oral 35 mg daily dose, 3 capsules per dose during a six week treatment period.
oral 5 mg daily dose, 3 capsules per dose during a six week treatment period.
oral 50 mg daily dose, 3 capsules per dose during a six week treatment period.
|
|
Experimental: 5 mg
|
oral 15 mg daily dose, 3 capsules per dose during a six week treatment period.
oral 25 mg daily dose, 3 capsules per dose during a six week treatment period.
oral 35 mg daily dose, 3 capsules per dose during a six week treatment period.
oral 5 mg daily dose, 3 capsules per dose during a six week treatment period.
oral 50 mg daily dose, 3 capsules per dose during a six week treatment period.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Total score of how an individual rates the restorative value of his/her sleep in the morning using the weekly version of the Restorative Sleep Questionnaire (RSQ-Weekly)
Time Frame: Weekly
|
Weekly
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Measure sleep and early morning behavior during treatment using the Leeds Sleep Evaluation Questionnaire
Time Frame: Weeky
|
Weeky
|
|
Total score of the Daily Restorative Sleep Questionnaire
Time Frame: Daily
|
Daily
|
|
Total score of the Multidimensional Assessment of Fatigue (MAF)
Time Frame: Weekly
|
Weekly
|
|
Total score of the Sheehan Disability Scale to measure functional impairment
Time Frame: Weekly
|
Weekly
|
|
Measure of health status using the Medical Outcomes Study Short Form-36 (SF-36v2-Acute)
Time Frame: Weekly
|
Weekly
|
|
Total mood disturbance score using the Profile of Mood State-Short Form Questionnaire (POMS-SF)
Time Frame: Weekly
|
Weekly
|
|
Total score of the Endicott Work Productivity Scale (EWPS) measuring work productivity.
Time Frame: Weekly
|
Weekly
|
|
Disease severity and change using the Clinical Global Impression of Severity (CGI-S) as rated by the Clinician.
Time Frame: Weekly
|
Weekly
|
|
Disease change (patient rated) measure using the Patient Global Impression of Change (PGIC).
Time Frame: Weekly
|
Weekly
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- A4251033
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.